AXNMAN
2 years ago
The pr's line up....
first there is talk about. Electromedical surrounding. Magic mushrooms....
So the intelligent among us. Rules out recreational magic mushrooms and starts looking at the opportunity. The opportunity in the medical area.
Then we see. An acquisition of AVAIL labs.
Next we see. A PR. About $6 million. Revenue potential in South Florida from the. CEO of a male labs.
Then we see a $25 million line of credit for the. Purchase. Of these electromedical devices, which will allow experts to read the neural pathways in. Suicidal. Veterans. In people who are addicted to heroin, in alcoholics, et cetera,
I am beginning to see. On the wall.
The future for Magic mushrooms. I would say Silocybin, if I could spell it easily.
The future is in medicine, not in recreation. Make note of that. Everybody.
MRc2
2 years ago
Avail Scientific Appoints Gerard Maynard as Chief Revenue Officer
Jan 31, 2023 (ACCESSWIRE via COMTEX) -- TORONTO, ON / ACCESSWIRE / January 31, 2023 / MOBILE LADS, CORP., dba AVAIL SCIENTIFIC (OTC PINK:MOBO), is pleased to announce Gerard Maynard as Chief Revenue Officer ("CRO"). Following Avail's January 10th, 2023, Letter of Intent that outlined the terms for the acquisition of Relai Neuro at which Gerard Maynard is currently President. Gerard has over twenty years of experience building, and leading successful sales organizations, in digital marketing, healthcare, technology and IT management.
"I couldn't be more thrilled to join such an amazing organization as Avail Scientific. With Avail's new venture into neurological testing, data management as well as strategic partnerships in the mental health industry. This is a golden opportunity to drive revenues via Avail's neurological testing and analytics while building our strategic partnerships and long-term value. Avail is poised to have exponential growth over the next few years. I feel very fortunate to be a party of such a talented team" statement from Gerard Maynard Relai Neuro provides neurological testing and data management to rehab and mental health treatment centers in Florida. Avail Scientific's (MOBO) mandate is to support psychedelic medicine research and treatments through neurological testing, data analytics, and data management.
Website: https://www.relaineuro.com
Website: https://www.availscientific.com/
https://www.marketwatch.com/press-release/avail-scientific-appoints-gerard-maynard-as-chief-revenue-officer-2023-01-31?mod=mw_quote_news_seemore
MRc2
2 years ago
Relai Neuro CEO Appointed as Interim CEO to Avail Scientific
TORONTO, ON / ACCESSWIRE / January 26, 2023 / MOBILE LADS CORP, doing business as AVAIL SCIENTIFIC ("AVAIL") / (OTC PINK:MOBO) is pleased to announce Dr. James Thompson will be appointed as Interim CEO of Avail Scientific. This appointment follows Avail's January 10th, 2023 announcement of having signed a Letter of Intent that outlined the terms for the acquisition of Relai Neuro at which Dr. Thompson is currently CEO.
Dr. Thompson's professional experience in neurological testing and analytics, his work in founding, growing, and consulting with medical technology companies, and his passion for the mental health space will be instrumental in guiding Avail Scientific's pursuit of supporting psychedelic medicine research and treatments through neurological testing, data analytics, and data management.
Dr. Thompson states, "I am excited to help lead Avail Scientific. One of my first goals will be to build out our management team as well as to establish key strategic partnerships over the next few months in order to position us to achieve our collective mission."
Current CEO, Michael Paul will retain his role as President and Chairman of the Board of Directors of Avail. "We are excited to have Dr. Thompson take on the Interim CEO role at Avail as it aligns itself with Relai Neuro to become a much stronger single company. We are confident that Dr. Thompson can help drive the company toward its goal of becoming a world leader in the development of psychedelic therapeutics for the treatment of addiction & mental health issues," said Michael Paul.
https://finance.yahoo.com/news/relai-neuro-ceo-appointed-interim-150000986.html
MRc2
2 years ago
Avail Scientific Signs LOI to Acquire Florida Neurological Testing Company Relai Neuro
Jan 19, 2023 (ACCESSWIRE via COMTEX) -- TORONTO, ON / ACCESSWIRE / January 19, 2023 / AVAIL SCIENTIFIC (OTC PINK:MOBO) is pleased to announce it is entering into a letter of intent (LOI) to acquire Florida based Relai Neuro LLC which provides Neurological testing and data management.
This acquisition will allow Relai to double its sales force over the next three months as well as expand services into California, Texas, and Colorado.
Dr. James Thompson, CEO of Relai Neuro, says; "We are excited to work with Avail Scientific. The acquisition will allow us to bolster our offerings and our team. Additionally, the acquisition of Relai will allow us to achieve our goals of expansion in Florida, as well as expand quickly into California, Texas, and Colorado markets."
"Relai Nero allows Avail to continue to accelerate our treatment applications, testing and supporting data collection as we strive to become a world leader in the clinically studied and supported use of psychedelic therapeutics for treatment of addiction & mental health issues," says Avail CEO, Michael Paul.
Relai Neuro provides neurological testing and data management to rehab and mental health treatment centres in Florida.
Relai's products and methodology allow for the direct measurement of progress in neural functions of patients under various treatments. For example, Relai is currently measuring the effects of Psilocybin micro-dosing on addiction in patients within a clinical environment.
RelaiNeuro - https://nusqu.com/relaineuro
https://www.marketwatch.com/press-release/avail-scientific-signs-loi-to-acquire-florida-neurological-testing-company-relai-neuro-2023-01-19?mod=mw_quote_news_seemore
MRc2
2 years ago
Mobile Lads/Avail Scientific to Enter the Neurological Testing and Data Management Area with A Continued Emphasis on Monitoring the Effectiveness of Psychedelic Medicines in Mental Health Treatment Via Software and Hardware Systems
Avail Scientific will be focusing its efforts on neurological data acquisition, data analysis, and data management with the explicit goal of better understanding and improving patient outcomes in multiple neurological disorders, with an initial focus on mental health and addiction.
Avail Scientific is continuing to establish key partners in the psychedelic medicine space to monitor the effectiveness and efficacy of Psychedelic medicines in mental health treatment as these modalities continue to demonstrate heightened effectiveness and gain regulatory acceptance.
Avail Scientific has been evaluating several promising ventures with research organizations and manufacturing laboratories for some time and expects to conclude several business partnerships in the near-term.
Avail Scientific's mandate is to support neurological, psychedelic and other medical research and treatments through neurological testing, data analytics and data management.
https://www.marketwatch.com/press-release/mobile-ladsavail-scientific-to-enter-the-neurological-testing-and-data-management-area-with-a-continued-emphasis-on-monitoring-the-effectiveness-of-psychedelic-medicines-in-mental-health-treatment-via-software-and-hardware-systems-2023-01-06?mod=mw_quote_news_seemore
MRc2
2 years ago
Mobile Lads/Avail Scientific to Enter the Neurological Testing and Data Management Area with A Continued Emphasis on Monitoring the Effectiveness of Psychedelic Medicines in Mental Health Treatment Via Software and Hardware Systems
Avail Scientific will be focusing its efforts on neurological data acquisition, data analysis, and data management with the explicit goal of better understanding and improving patient outcomes in multiple neurological disorders, with an initial focus on mental health and addiction.
Avail Scientific is continuing to establish key partners in the psychedelic medicine space to monitor the effectiveness and efficacy of Psychedelic medicines in mental health treatment as these modalities continue to demonstrate heightened effectiveness and gain regulatory acceptance.
Avail Scientific has been evaluating several promising ventures with research organizations and manufacturing laboratories for some time and expects to conclude several business partnerships in the near-term.
Avail Scientific's mandate is to support neurological, psychedelic and other medical research and treatments through neurological testing, data analytics and data management.
https://www.marketwatch.com/press-release/mobile-ladsavail-scientific-to-enter-the-neurological-testing-and-data-management-area-with-a-continued-emphasis-on-monitoring-the-effectiveness-of-psychedelic-medicines-in-mental-health-treatment-via-software-and-hardware-systems-2023-01-06?mod=mw_quote_news_seemore
BigJuan
2 years ago
$MOBO SS float reduction
$MOBO
??0.0140
Pink Current, AS: 950M, OS: 368M, US: 172M
Restricted Shares Updated:
- 143,296,294 (2022-11-15)
+ 196,096,294 (2022-12-12)
Difference: +36.8% (+52M)
Unrestricted Shares Updated:
- 225,698,590 (2022-11-15)
+ 172,898,590 (2022-12-12)
Difference: -23.4% (-52M)
Chart, OTC Profile, Twitter, @otcupdates
Update: 2022-12-13 15:16:52 (UTC)